Claros Diagnostics

ExQor Technologies Inc, based in Boston, MA, is pioneering a unique biologic aimed at restoring cognitive capabilities by regenerating damaged neurons and their connections, specifically targeting neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementia. Unlike conventional drugs that merely delay disease progression, ExQor's innovative approach holds promise for treating various central nervous system disorders, including depression. The company is actively preparing its first Investigational New Drug (IND) applications to the FDA for addressing cognitive impairments associated with dementia. Additionally, ExQor is advancing diagnostic programs utilizing MRI and EEG technologies to detect early-stage Alzheimer's and mild cognitive impairment, which could lead to personalized treatment solutions and significant advancements in global healthcare. Generated from the website

Target Molecule Corp, located in Boston, MA, specializes in providing a comprehensive range of innovative biochemical products and services tailored for molecular and cellular research. Their extensive catalog includes inhibitors, agonists, compound libraries, and diverse natural products aimed at advancing research in areas such as autophagy, cancer, and immunology. The company is committed to improving the user experience with intuitive search features, product comparisons, and community engagement through reviews and feedback. Target Molecule Corp also offers focused bioactive libraries and technical services to support researchers in their scientific endeavors. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.